Finance

Lists
NOVA:FRA
Novo Nordisk A/S
€35,80
0,00%
(0,00) 1D
18 ພ.ຈ., 21 ໂມງ 48 ນາທີ 56 ວິນາທີ GMT+1  ·   EUR
All symbols
SymbolPriceChange% Change
Generating top insights for NOVA...
Mkt. cap
133,14 ຕື້
Avg. vol.
650,00
Volume
0,00
52-wk high
€54,80
52-wk low
€30,45
No. of employees
67 ພັນ
Mkt. cap
133,14 ຕື້
Avg. vol.
650,00
Volume
0,00
52-wk high
€54,80
52-wk low
€30,45
No. of employees
67 ພັນ
News stories
From web sources and news partners
Profile
Novo Nordisk A/S, doing business as Novo, is a Danish multinational pharmaceutical company. Novo manufactures and markets pharmaceutical products and services, primarily obesity and diabetes medications and devices. The corporation was created in 1989, through a merger of two Danish pharmaceutical companies, which date back to the 1920s. Novo employs approximately 69,500 people in 80 countries, and markets its products in approximately 170 countries. Novo is controlled by majority shareholder Novo Holdings which holds 28% of its shares and a majority of its voting shares. Novo is a full member of the European Federation of Pharmaceutical Industries and Associations. The company was ranked 25th among Fortune's 100 Best Companies to Work For in 2010, and subsequently ranked 72nd in 2014 and 73rd in 2017. In January 2012, Novo was named the most sustainable company in the world by the business magazine Corporate Knights. It is a leader in the FTSE4Good Index, and the only European company in the top ten. Novo is the largest pharmaceutical company in Denmark. In 2023, Novo's market capitalization exceeded the GDP of Denmark, and it became the highest valued company in Europe. Wikipedia
About Novo Nordisk A/S
CEOMike Doustdar
Employees66,7 ພັນ
Founded1923
HeadquartersBagsværd, Capital Region of Denmark, ເດນມາກ
SectorHealth Care
IndustryPharmaceutical industry
Previous reportsAll values in DKK
Loading Previous Earnings...
Revenue
Net income
All values in DKK
ທ.ວ. 2025
ມ.ນ. 2026
ມິ.ຖ. 2026
ກ.ຍ. 2026
Revenue
79,14 ຕື້
96,82 ຕື້
78,49 ຕື້
79,20 ຕື້
Cost of goods sold
14,17 ຕື້
13,60 ຕື້
17,10 ຕື້
14,18 ຕື້
Cost of revenue
14,17 ຕື້
13,60 ຕື້
17,10 ຕື້
14,18 ຕື້
Research and development expenses
12,67 ຕື້
10,28 ຕື້
11,46 ຕື້
15,26 ຕື້
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
17,14 ຕື້
13,22 ຕື້
16,31 ຕື້
16,26 ຕື້
Operating expense
29,73 ຕື້
23,61 ຕື້
28,00 ຕື້
33,30 ຕື້
Total operating expenses
43,90 ຕື້
37,20 ຕື້
45,10 ຕື້
47,48 ຕື້
Operating income
35,24 ຕື້
59,62 ຕື້
33,39 ຕື້
31,72 ຕື້
Other non operating income
-241,00 ລ້ານ
-
-
-443,00 ລ້ານ
EBT including unusual items
34,18 ຕື້
62,17 ຕື້
26,88 ຕື້
21,43 ຕື້
EBT excluding unusual items
37,62 ຕື້
62,17 ຕື້
33,20 ຕື້
30,14 ຕື້
Income tax expense
7,29 ຕື້
13,62 ຕື້
5,89 ຕື້
4,69 ຕື້
Effective tax rate
21,34%
21,90%
21,90%
21,90%
Other operating expenses
-81,00 ລ້ານ
106,00 ລ້ານ
234,00 ລ້ານ
1,79 ຕື້
Net income
26,89 ຕື້
48,56 ຕື້
20,99 ຕື້
16,74 ຕື້
Net profit margin
33,98%
50,15%
26,74%
21,14%
Earnings per share
6,04
6,63
6,18
5,79
Interest and investment income
4,41 ຕື້
-
1,31 ຕື້
-
Interest expense
-4,97 ຕື້
-
-1,50 ຕື້
-1,13 ຕື້
Net interest expenses
-560,00 ລ້ານ
-
-186,00 ລ້ານ
-1,13 ຕື້
Depreciation and amortization charges
-
-
-
-
EBITDA
36,66 ຕື້
63,13 ຕື້
36,99 ຕື້
35,32 ຕື້
Gain or loss from assets sale
-
-
-
-
Upcoming events
AI content may include mistakes. Learn more
ແອັບຂອງ Google